After 1 year of gefitinib treatment, we successfully established a gefitinib-resistant NSCLC cell line PC9GR from the gefitinib-sensitive PC9 cell line, which is derived from lung adenocarcinoma with a typical EGFR mutation on exon19 (15 base deletion). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.